# US 2003/0215823 A1 · Uses of galanin GALR2 receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215823 A1
- Document ID: US20030215823A1
- Status: Published application
- Kind: A1
- Application number: 10/285,019
- Filed: 2002-10-31
- Published: 2003-11-20
- Earliest claimed: 1996-01-24
- Assignees: Synaptic Pharmaceutical Corporation
- Inventors: Kelli E. Smith; David Linemeyer; Christophe P. G. Gerald; Theresa Branchek; Richard L. Weinshank; Carlos Forray
- Web page: https://patentgrep.com/patent/US20030215823A1

## CPC

- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

## Claims

### Claim 1

An isolated nucleic acid encoding a GALR2 receptor.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid is DNA.

### Claim 3 (depends on 2)

The DNA of claim 2, wherein the DNA is cDNA.

### Claim 4 (depends on 2)

The DNA of claim 2, wherein the DNA is genomic DNA.

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid is RNA.

### Claim 6 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid encodes a vertebrate GALR2 receptor.

### Claim 7 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid encodes a mammalian GALR2 receptor.

### Claim 8 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid encodes a rat GALR2 receptor.

### Claim 9 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid encodes a human GALR2 receptor.

### Claim 10 (depends on 7)

The nucleic acid of claim 7, wherein the nucleic acid encodes a receptor characterized by an amino acid sequence in the transmembrane region which has a homology of 60% or higher to the amino acid sequence in the transmembrane region of the rat GALR2 receptor and a homology of less than 60% to the amino acid sequence in the transmembrane region of any GALR1 receptor.

### Claim 11 (depends on 7)

The nucleic acid of claim 7, wherein the nucleic acid encodes a mammalian GALR2 receptor which has substantially the same amino acid sequence as does the GALR2 receptor encoded by the plasmid K985 (ATCC Accession No. 97426).

### Claim 12 (depends on 8)

The nucleic acid of claim 8, wherein the nucleic acid encodes a rat GALR2 receptor which has an amino acid sequence encoded by the plasmid K985 (ATCC Accession No. 97426).

### Claim 13 (depends on 7)

The nucleic acid of claim 7, wherein the nucleic acid encodes a mammalian GALR2 receptor which has substantially the same amino acid sequence as does the GALR2 receptor encoded by the plasmid K1045 (ATCC Accession No. 97778).

### Claim 14 (depends on 8)

The nucleic acid of claim 8, wherein the nucleic acid encodes a rat GALR2 receptor which has an amino acid sequence encoded by the plasmid K1045 (ATCC Accession No. 97778).

### Claim 15 (depends on 8)

The nucleic acid of claim 8, wherein the nucleic acid encodes a rat GALR2 receptor which has substantially the same amino acid sequence as that shown in FIG. 2.

### Claim 16 (depends on 8)

The nucleic acid of claim 8, wherein the nucleic acid encodes a rat GALR2 receptor which has the amino acid sequence shown in FIG. 2.

### Claim 17 (depends on 7)

The nucleic acid of claim 7, wherein the nucleic acid encodes a mammalian GALR2 receptor which has substantially the same amino acid sequence as does the GALR2 receptor encoded by the plasmid BO29 (ATCC Accession No. 97735).

### Claim 18 (depends on 9)

The nucleic acid of claim 9, wherein the nucleic acid encodes a human GALR2 receptor which has an amino acid sequence encoded by the plasmid BO29 (ATCC Accession No. 97735).

### Claim 19 (depends on 7)

The nucleic acid of claim 7, wherein the nucleic acid encodes a mammalian GALR2 receptor which has substantially the same amino acid sequence as does the GALR2 receptor encoded by the plasmid BO39 (ATCC Accession No. 97851).

### Claim 20 (depends on 9)

The nucleic acid of claim 9, wherein the nucleic acid encodes a human GALR2 receptor which has an amino acid sequence encoded by the plasmid BO39 (ATCC Accession No. 97851).

### Claim 21 (depends on 9)

The nucleic acid of claim 9, wherein the nucleic acid encodes a human GALR2 receptor which has substantially the same amino acid sequence as that shown in FIG. 11.

### Claim 22 (depends on 9)

The nucleic acid of claim 9, wherein the nucleic acid encodes a human GALR2 receptor which has the amino acid sequence shown in FIG. 11.

### Claim 23

An isolated nucleic acid encoding a modified GALR2 receptor, which differs from a GALR2 receptor by having an amino acid(s) deletion, replacement or addition in the third intracellular domain.

### Claim 24 (depends on 23)

The nucleic acid of claim 23, wherein the modified GALR2 receptor differs from a GALR2 receptor by having a deletion in the third intracellular domain.

### Claim 25 (depends on 23)

The nucleic acid of claim 23, wherein the modified GALR2 receptor differs from a GALR2 receptor by having a replacement or addition in the third intracellular domain.

### Claim 26

A purified GALR2 receptor protein.

### Claim 27 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 28 (depends on 8, 9)

A vector comprising the nucleic acid of either of claims 8 or 9.

### Claim 29 (depends on 27)

A vector of claim 27 adapted for expression in a bacterial cell which comprises the regulatory elements necessary for expression of the nucleic acid in the bacterial cell operatively linked to the nucleic acid encoding a GALR2 receptor as to permit expression thereof.

### Claim 30 (depends on 27)

A vector of claim 27 adapted for expression in a yeast cell which comprises the regulatory elements necessary for expression of the nucleic acid in the yeast cell operatively linked to the nucleic acid encoding a GALR2 receptor as to permit expression thereof.

### Claim 31 (depends on 27)

A vector of claim 27 adapted for expression in an insect cell which comprises the regulatory elements necessary for expression of the nucleic acid in the insect cell operatively linked to the nucleic acid encoding the GALR2 receptor as to permit expression thereof.

### Claim 32 (depends on 31)

A vector of claim 31 which is a baculovirus.

### Claim 33 (depends on 27)

A vector of claim 27 adapted for expression in a mammalian cell which comprises the regulatory elements necessary for expression of the nucleic acid in the mammalian cell operatively linked to the nucleic acid encoding a GALR2 receptor as to permit expression thereof.

### Claim 34 (depends on 27)

A vector of claim 27 wherein the vector is a plasmid.

### Claim 35 (depends on 34)

The plasmid of claim 34 designated K985 (ATCC Accession No. 97426).

### Claim 36 (depends on 34)

The plasmid of claim 34 designated K1045 (ATCC Accession No. 97778).

### Claim 37 (depends on 34)

The plasmid of claim 34 designated BO29 (ATCC Accession No. 97735).

### Claim 38 (depends on 34)

The plasmid of claim 34 designated BO39 (ATCC Accession No. 97851).

### Claim 39 (depends on 27)

A cell comprising the vector of claim 27.

### Claim 40 (depends on 39)

A cell of claim 39, wherein the a non-mammalian cell.

### Claim 41 (depends on 40)

A cell of claim 40, wherein the non-mammalian cell is a Xenopus oocyte cell or a Xenopus melanophore cell.

### Claim 42 (depends on 39)

A cell of claim 39, wherein the cell is a mammalian cell.

### Claim 43 (depends on 42)

A mammalian cell of claim 42, wherein the cell is a nucleotides, which probe specifically hybridizes with a nucleic acid encoding a GALR2 receptor, wherein the probe has a unique sequence corresponding to a sequence present within one of the two strands of the nucleic acid encoding the GALR2 receptor contained in plasmid K1045.

### Claim 54

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a GALR2 receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in FIG. 1 or (b) the reverse complement of the nucleic acid sequence shown in FIG. 1.

### Claim 55

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a GALR2 receptor, wherein the probe has a unique sequence corresponding to a sequence present within one of the two strands of the nucleic acid encoding the GALR2 receptor contained in plasmid BO29.

### Claim 56

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a GALR2 receptor, wherein the probe has a unique sequence corresponding to a sequence present within one of the two strands of the nucleic acid encoding the GALR2 receptor contained in plasmid BO39.

### Claim 57

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a GALR2 receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in FIG. 10 or (b) the reverse complement of the nucleic acid sequence shown in FIG. 10.

### Claim 58 (depends on 52, 53, 54, 55, 56, 57)

The nucleic acid probe of any one of claims 52, 53, 54, 55, 56 or 57, wherein the nucleic acid is DNA.

### Claim 59 (depends on 52, 53, 54, 55, 56, 57)

The nucleic acid probe of any one of claims 52, 53, 54, 55, 56 or 57 wherein the nucleic acid is RNA.

### Claim 60

A nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides which is complementary to a unique fragment of the sequence of a nucleic acid molecule encoding a GALR2 receptor.

### Claim 61

A nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a GALR2 receptor.

### Claim 62 (depends on 5)

An antisense oligonucleotide having a sequence capable of specifically hybridizing to the mRNA of claim 5, so as to prevent translation of the mRNA.

### Claim 63 (depends on 4)

An antisense oligonucleotide having a sequence capable of specifically hybridizing to the genomic DNA of claim 4.

### Claim 64 (depends on 62, 63)

An antisense oligonucleotide of either of claims 62 or 63, wherein the oligonucleotide comprises chemically modified nucleotides or nucleotide analogues.

### Claim 65 (depends on 1)

An antibody capable of binding to a GALR2 receptor encoded by the nucleic acid of claim 1.

### Claim 66 (depends on 65)

The antibody of claim 65, wherein the GALR2 receptor is a human GALR2 receptor.

### Claim 67 (depends on 65)

An antibody capable of competitively inhibiting the binding of the antibody of claim 65 to a GALR2 receptor.

### Claim 68 (depends on 65)

An antibody of claim 65, wherein the antibody is a monoclonal antibody.

### Claim 69 (depends on 68)

A monoclonal antibody of claim 68 directed to an epitope of a GALR2 receptor present on the surface of a GALR2 receptor expressing cell.

### Claim 70 (depends on 62)

A pharmaceutical composition comprising an amount of the oligonucleotide of claim 62 capable of passing through a cell membrane effective to reduce expression of a GALR2 receptor and a pharmaceutically acceptable carrier capable of passing through a cell membrane.

### Claim 71 (depends on 70)

A pharmaceutical composition of claim 70, wherein the oligonucleotide is coupled to a substance which inactivates mRNA.

### Claim 72 (depends on 71)

A pharmaceutical composition of claim 71, wherein the substance which inactivates mRNA is a ribozyme.

### Claim 73 (depends on 70)

A pharmaceutical composition of claim 70, wherein the pharmaceutically acceptable carrier comprises a structure which binds to a receptor on a cell capable of being taken up by the cells after binding to the structure.

### Claim 74 (depends on 73)

A pharmaceutical composition of claim 73, wherein the pharmaceutically acceptable carrier is capable of binding to a receptor which is specific for a selected cell type.

### Claim 75 (depends on 65)

A pharmaceutical composition which comprises an amount of the antibody of claim 65 effective to block binding of a ligand to the GALR2 receptor and a pharmaceutically acceptable carrier.

### Claim 76 (depends on 1)

A transgenic nonhuman mammal expressing DNA encoding a GALR2 receptor of claim 1.

### Claim 77

A transgenic nonhuman mammal comprising a homologous recombination knockout of the native GALR2 receptor.

### Claim 78 (depends on 1)

A transgenic nonhuman mammal whose genome comprises antisense DNA complementary to DNA encoding a GALR2 receptor of claim 1 so placed as to be transcribed into antisense mRNA which is complementary to mRNA encoding a GALR2 receptor and which hybridizes to mRNA encoding a GALR2 receptor, thereby reducing its translation.

### Claim 79 (depends on 76, 77)

The transgenic nonhuman mammal of claim 76 or 77, wherein the DNA encoding a GALR2 receptor additionally comprises an inducible promoter.

### Claim 80 (depends on 76, 78)

The transgenic nonhuman mammal of claim 76 or 78, wherein the DNA encoding a GALR2 receptor additionally comprises tissue specific regulatory elements.

### Claim 81 (depends on 76, 77, 78)

A transgenic nonhuman mammal of any one of claims 76, 77 or 78, wherein the transgenic nonhuman mammal is a mouse.

### Claim 82

A process for identifying a chemical compound which specifically binds to a GALR2 receptor which comprises contacting cells containing DNA encoding and expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the GALR2 receptor.

### Claim 83

A process for identifying a chemical compound which specifically binds to a GALR2 receptor which comprises contacting a membrane fraction from a cell extract of cells containing DNA encoding and expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the GALR2 receptor.

### Claim 84 (depends on 82, 83)

The process of claim 82 or 83, wherein the GALR2 receptor is a mammalian GALR2 receptor.

### Claim 85 (depends on 82, 83)

The process of claim 82 or 83, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid K985 (ATCC Accession No. 97426).

### Claim 86 (depends on 82, 83)

The process of claim 82 or 83, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 2 (Seq. ID No. 8).

### Claim 87 (depends on 82, 83)

The process of claim 82 or 83, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid BO29 (ATCC Accession No. 97735).

### Claim 88 (depends on 82, 83)

The process of claim 82 or 83, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 11 (Seq. ID No. 30).

### Claim 89 (depends on 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 82, 83, 84, 85, 86, 87 or 88, wherein the compound is not previously known to bind to a GALR2 receptor.

### Claim 90 (depends on 89)

A compound determined by the method of claim 89.

### Claim 91

A process for determining whether a chemical compound is a GALR2 receptor agonist which comprises contacting cells transfected with and expressing DNA encoding the GALR2 receptor with the compound under conditions permitting the activation of the GALR2 receptor, and detecting an increase in GALR2 receptor activity, so as to thereby determine whether the compound is a GALR2 receptor agonist.

### Claim 92

A process for determining whether a chemical compound is a GALR2 receptor agonist which comprises preparing a cell extract from cells transfected with and expressing DNA encoding the GALR2 receptor, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the compound under conditions permitting the activation of the GALR2 receptor, and detecting an increase in GALR2 receptor activity, so as to thereby determine whether the compound is a GALR2 receptor agonist.

### Claim 93

A process for determining whether a chemical compound is a GALR2 receptor agonist which comprises preparing a cell extract from cells transfected with and expressing DNA encoding the GALR2 receptor, isolating a membrane fraction from the cell extract, separately contacting the membrane fraction with both the chemical compound and GTPγS, and with only GTPγS, under conditions permitting the activation of the GALR2 receptor, and detecting GTPγS binding to the membrane fraction, an increase in GTPγS binding in the presence of the compound indicating that the chemical compound activates the GALR2 receptor.

### Claim 94 (depends on 91, 92, 93)

The process of any one of claims 91, 92 or 93, wherein the GALR2 receptor is a mammalian GALR2 receptor.

### Claim 95 (depends on 91, 92)

The process of any one of claims 91 or 92, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid K985 (ATCC Accession No. 97426).

### Claim 96 (depends on 91, 92)

The process of claim 91 or 92, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 2 (Seq. ID No. 8).

### Claim 97 (depends on 91, 92)

The process of claim 91 or 92, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid BO29 (ATCC Accession No. 97735).

### Claim 98 (depends on 91, 92)

The process of claim 91 or 92, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 11 (Seq. ID No. 30).

### Claim 99

A process for determining whether a chemical compound is a GALR2 receptor antagonist which comprises contacting cells transfected with and expressing DNA encoding the GALR2 receptor with the compound in the presence of a known GALR2 receptor agonist, under conditions permitting the activation of the GALR2 receptor, and detecting a decrease in GALR2 receptor activity, so as to thereby determine whether the compound is a GALR2 receptor antagonist.

### Claim 100

A process for determining whether a chemical compound is a GALR2 receptor antagonist which comprises preparing a cell extract from cells transfected with and expressing DNA encoding the GALR2 receptor, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the ligand in the presence of a known GALR2 receptor agonist, under conditions permitting the activation of the GALR2 receptor, and detecting a decrease in GALR2 receptor activity, so as to thereby determine whether the compound is a GALR2 receptor antagonist.

### Claim 101 (depends on 99, 100)

The process of claim 99 or 100, wherein the GALR2 receptor is a mammalian GALR2 receptor.

### Claim 102 (depends on 99, 100)

The process of claim 99 or 100, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid K985 (ATCC Accession No. 97426).

### Claim 103 (depends on 99, 100)

The process of claim 99 or 100, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 2 (Seq. ID No. 8).

### Claim 104 (depends on 99, 100)

The process of claim 99 or 100, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid BO29 (ATCC Accession No. 97735).

### Claim 105 (depends on 99, 100)

The process of claim 99 or 100, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 11 (Seq. ID No. 30).

### Claim 106 (depends on 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The process of any one of claims 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 or 105, wherein the cell is an insect cell.

### Claim 107 (depends on 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The process of any one of claims 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104 or 105, wherein the cell is a mammalian cell.

### Claim 108 (depends on 107)

The process of claim 107, wherein the cell is normeuronal in origin.

### Claim 109 (depends on 108)

The process of claim 108, wherein the normeuronal cell is a COS-7 cell, 293 human embryonic kidney cell, CHO cell, NIH-3T3 cell or LM(tk−) cell.

### Claim 110 (depends on 108)

The process of claim 108, wherein the normeuronal cell is the LM(tk−) cell designated L-rGALR2-8 (ATCC Accession No. CRL-12074).

### Claim 111 (depends on 108)

The process of claim 108, wherein the normeuronal cell is the LM(tk−) cell designated L-rGALR2I-4 (ATCC Accession No. CRL-12223).

### Claim 112 (depends on 108)

The process of claim 108, wherein the normeuronal cell is the CHO cell designated C-rGalR2-79 (ATCC Accession No. CRL-12262).

### Claim 113 (depends on 107)

The process of claim 107 wherein the compound is not previously known to bind to a GALR2 receptor.

### Claim 114 (depends on 113)

A compound determined by the process of claim 113.

### Claim 115 (depends on 91, 92, 93)

A pharmaceutical composition which comprises an amount of a GALR2 receptor agonist determined by the process of any one of claims 91, 92 or 93 effective to increase activity of a GALR2 receptor and a pharmaceutically acceptable carrier.

### Claim 116 (depends on 115)

A pharmaceutical composition of claim 115, wherein the GALR2 receptor agonist is not previously known.

### Claim 117 (depends on 99, 100)

A pharmaceutical composition which comprises an amount of a GALR2 receptor antagonist determined by the process of claim 99 or 100 effective to reduce activity of a GALR2 receptor and a pharmaceutically acceptable carrier.

### Claim 118 (depends on 117)

A pharmaceutical composition of claim 117, wherein the GALR2 receptor antagonist is not previously known.

### Claim 119

A process involving competitive binding for identifying a chemical compound which specifically binds to a GALR2 receptor which comprises separately contacting cells expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the GALR2 receptor, a decrease in the binding of the second chemical compound to the GALR2 receptor in the presence of the chemical compound indicating that the chemical compound binds to the GALR2 receptor.

### Claim 120

A process involving competitive binding for identifying a chemical compound which specifically binds to a human GALR2 receptor which comprises separately contacting a membrane fraction from a cell extract of cells expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the GALR2 receptor, a decrease in the binding of the second chemical compound to the GALR2 receptor in the presence of the chemical compound indicating that the chemical compound binds to the GALR2 receptor.

### Claim 121

A process for determining whether a chemical compound specifically binds to and activates a GALR2 receptor, which comprises contacting cells producing a second messenger response and expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with the chemical compound under conditions suitable for activation of the GALR2 receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the GALR2 receptor.

### Claim 122

A process for determining whether a chemical compound specifically binds to and activates a GALR2 receptor, which comprises contacting a membrane fraction isolated from a cell extract of cells producing a second messenger response and expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with the chemical compound under conditions suitable for activation of the GALR2 receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the GALR2 receptor.

### Claim 123

A process for determining whether a chemical compound specifically binds to and inhibits activation of a GALR2 receptor, which comprises separately contacting cells producing a second messenger response and expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with both the chemical compound and a second chemical compound known to activate the GALR2 receptor, and with only the second chemical compound, under conditions suitable for activation of the GALR2 receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the GALR2 receptor.

### Claim 124

A process for determining whether a chemical compound specifically binds to and inhibits activation of a GALR2 receptor, which comprises separately contacting a membrane fraction from a cell extract of cells producing a second messenger response and expressing on their cell surface the GALR2 receptor, wherein such cells do not normally express the GALR2 receptor, with both the chemical compound and a second chemical compound known to activate the GALR2 receptor, and with only the second chemical compound, under conditions suitable for activation of the GALR2 receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the GALR2 receptor.

### Claim 125 (depends on 121, 122)

The process of claim 121 or 122, wherein the second messenger response comprises arachidonic acid release and the change in second messenger response is an increase in arachidonic acid levels.

### Claim 126 (depends on 121, 122)

The process of claim 121 or 122, wherein the second messenger response comprises intracellular calcium levels and the change in second messenger response is an increase in intracellular calcium levels.

### Claim 127 (depends on 121, 122)

The process of claim 121 or 122, wherein the second messenger response comprises inositol phospholipid hydrolysis and the change in second messenger response is an increase in inositol phospholipid hydrolysis.

### Claim 128 (depends on 123, 124)

The process of claim 123 or 124, wherein the second messenger response comprises arachidonic acid release and the change in second messenger response is a smaller increase in the level of arachidonic acid in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.

### Claim 129 (depends on 123, 124)

The process of claim 123 or 124, wherein the second messenger response comprises intracellular calcium levels, and the change in second messenger response is a smaller increase in the intracellular calcium levels in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.

### Claim 130 (depends on 123, 124)

The process of claim 123 or 124, wherein the second messenger response comprises inositol phospholipid hydrolysis, and the change in second messenger response is a smaller increase in inositol phospholipid hydrolysis in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.

### Claim 131 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)

A process of any one of claims 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129 or 130, wherein the GALR2 receptor is a mammalian GALR2 receptor.

### Claim 132 (depends on 131)

The process of claim 131, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid K985 ATCC Accession No. 97426).

### Claim 133 (depends on 131)

The process of claim 131, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 2 (Seq. ID No. 8).

### Claim 134 (depends on 131)

The process of claim 131, wherein the GALR2 receptor has substantially the same amino acid sequence as encoded by the plasmid BO29 (ATCC Accession No. 97735).

### Claim 135 (depends on 131)

The process of claim 131, wherein the GALR2 receptor has substantially the same amino acid sequence as that shown in FIG. 11 (Seq. ID No. 30).

### Claim 136 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The process of any one of claims 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134 or 135, wherein the cell is an insect cell.

### Claim 137 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The process of any one of claims 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134 or 135, wherein the cell is a mammalian cell.

### Claim 138 (depends on 137)

The process of claim 137, wherein the mammalian cell is normeuronal in origin.

### Claim 139 (depends on 138)

The process of claim 138, wherein the normeuronal cell is a COS-7 cell, 293 human embryonic kidney cell, CHO cell, NIH-3T3 cell or LM(tk−) cell.

### Claim 140 (depends on 138)

The process of claim 138, wherein the normeuronal cell is the LM(tk−) cell designated L-rGALR2-8 (ATCC Accession No. CRL-12074).

### Claim 141 (depends on 138)

The process of claim 138, wherein the normeuronal cell is the LM(tk−) cell designated L-rGALR2I-4 (ATCC Accession No. CRL-12223).

### Claim 142 (depends on 138)

The process of claim 138, wherein the normeuronal cell is the CHO cell designated C-rGalR2-79 (ATCC Accession No. CRL-12262).

### Claim 143 (depends on 137)

The process of claim 137, wherein the compound is not previously known to bind to a GALR2 receptor.

### Claim 144 (depends on 143)

A compound determined by the process of claim 143.

### Claim 145 (depends on 121, 122, 125, 126)

A pharmaceutical composition which comprises an amount of a GALR2 receptor agonist determined by the process of any one of claims 121, 122, 125, 126, or 127 effective to increase activity of a GALR2 receptor and a pharmaceutically acceptable carrier.

### Claim 146 (depends on 145)

A pharmaceutical composition of claim 145, wherein the GALR2 receptor agonist is not previously known.

### Claim 147 (depends on 123, 124, 128, 129, 130)

A pharmaceutical composition which comprises an amount of a GALR2 receptor antagonist determined by the process of any one of claims 123, 124, 128, 129 or 130 effective to reduce activity of a GALR2 receptor and a pharmaceutically acceptable carrier.

### Claim 148 (depends on 147)

A pharmaceutical composition of claim 147, wherein the GALR2 receptor antagonist is not previously known.

### Claim 149

A method of screening a plurality of chemical compounds not known to bind to a GALR2 receptor to identify a compound which specifically binds to the GALR2 receptor, which comprises
(a) contacting cells transfected with and expressing DNA encoding the GALR2 receptor with a compound known to bind specifically to the GALR2 receptor;
(b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the GALR2 receptor, under conditions permitting binding of compounds known to bind the GALR2 receptor;
(c) determining whether the binding of the compound known to bind to the GALR2 receptor is reduced in the presence of the compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
(d) separately determining the binding to the GALR2 receptor of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the GALR2 receptor.

### Claim 150

A method of screening a plurality of chemical compounds not known to bind to a GALR2 receptor to identify a compound which specifically binds to the GALR2 receptor, which comprises
(a) preparing a cell extract from cells transfected with and expressing DNA encoding the GALR2 receptor, isolating a membrane fraction from the cell extract, contacting the membrane fraction with a compound known to bind specifically to the GALR2 receptor;
(b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the GALR2 receptor, under conditions permitting binding of compounds known to bind the GALR2 receptor;
(c) determining whether the binding of the compound known to bind to the GALR2 receptor is reduced in the presence of the compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
(d) separately determining the binding to the GALR2 receptor of each compound included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the GALR2 receptor.

### Claim 151 (depends on 149, 150)

A method of claim 149 or 150, wherein the GALR2 receptor is a mammalian GALR2 receptor.

### Claim 152

A method of screening a plurality of chemical compounds not known to activate a GALR2 receptor to identify a compound which activates the GALR2 receptor which comprises
(a) contacting cells transfected with and expressing the GALR2 receptor with the plurality of compounds not known to activate the GALR2 receptor, under conditions permitting activation of the GALR2 receptor;
(b) determining whether the activity of the GALR2 receptor is increased in the presence of the compounds; and if so
(c) separately determining whether the activation of the GALR2 receptor is increased by each compound included in the plurality of compounds, so as to thereby identify the compound which activates the GALR2 receptor.

### Claim 153

A method of screening a plurality of chemical compounds not known to activate a GALR2 receptor to identify a compound which activates the GALR2 receptor which comprises
(a) preparing a cell extract from cells transfected with and expressing DNA encoding the GALR2 receptor, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the plurality of compounds not known to activate the GALR2 receptor, under conditions permitting activation of the GALR2 receptor;
(b) determining whether the activity of the GALR2 receptor is increased in the presence of the compounds; and if so
(c) separately determining whether the activation of the GALR2 receptor is increased by each compound included in the plurality of compounds, so as to thereby identify the compound which activates the GALR2 receptor.

### Claim 154 (depends on 152, 153)

A method of claim 152 or 153, wherein the GALR2 receptor is a mammalian GALR2 receptor.

### Claim 155

A method of screening a plurality of chemical compounds not known to inhibit the activation of a GALR2 receptor to identify a compound which inhibits the activation of the GALR2 receptor, which comprises
(a) contacting cells transfected with and expressing the GALR2 receptor with the plurality of compounds in the presence of a known GALR2 receptor agonist, under conditions permitting activation of the GALR2 receptor;
(b) determining whether the activation of the GALR2 receptor is reduced in the presence of the plurality of compounds, relative to the activation of the GALR2 receptor in the absence of the plurality of compounds; and if so
(c) separately determining the inhibition of activation of the GALR2 receptor for each compound included in the plurality of compounds, so as to thereby identify the compound which inhibits the activation of the GALR2 receptor.

### Claim 156

A method of screening a plurality of chemical compounds not known to inhibit the activation of a GALR2 receptor to identify a compound which inhibits the activation of the GALR2 receptor, which comprises
(a) preparing a cell extract from cells transfected with and expressing DNA encoding the GALR2 receptor, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the plurality of compounds in the presence of a known GALR2 receptor agonist, under conditions permitting activation of the GALR2 receptor;
(b) determining whether the activation of the GALR2 receptor is reduced in the presence of the plurality of compounds, relative to the activation of the GALR2 receptor in the absence of the plurality of compounds; and if so
(c) separately determining the inhibition of activation of the GALR2 receptor for each compound included in the plurality of compounds, so as to thereby identify the compound which inhibits the activation of the GALR2 receptor.

### Claim 157 (depends on 91, 92, 93, 99, 100, 152, 153, 155)

A method of any one of claims 91, 92, 93, 99, 100, 152, 153, 155, or 156, wherein activation of the GALR2 receptor is determined by a second messenger assay.

### Claim 158 (depends on 157)

The method of claim 157, wherein the second messenger is arachidonic acid, intracellular calcium, or an inositol phospholipid.

### Claim 159 (depends on 155, 156)

A method of claim 155 or 156, wherein the GALR2 receptor is a mammalian GALR2 receptor.

### Claim 160 (depends on 149, 150, 152, 153, 155)

A method of any one of claims 149, 150, 152, 153, 155, or 156, wherein the cell is a mammalian cell.

### Claim 161 (depends on 160)

A method of claim 160, wherein the mammalian cell is non-neuronal in origin.

### Claim 162 (depends on 161)

The method of claim 161, wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a CHO cell, a LM(tk−) cell or an NIH-3T3 cell.

### Claim 163 (depends on 152)

A pharmaceutical composition comprising a compound identified by the method of claim 152 and a pharmaceutically acceptable carrier.

### Claim 164 (depends on 155)

A pharmaceutical composition comprising a compound identified by the method of claim 155 and a pharmaceutically acceptable carrier.

### Claim 165 (depends on 52, 53, 54, 55, 56, 57, 61)

A method of detecting expression of a GALR2 receptor by detecting the presence of mRNA coding for the GALR2 receptor which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the nucleic acid probe of any one of claims 52, 53, 54, 55, 56, 57 or 61 under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the GALR2 receptor by the cell.

### Claim 166 (depends on 117, 118)

A method of treating an abnormality in a subject, wherein the abnormality is alleviated by the inhibition of a GALR2 receptor which comprises administering to a subject an effective amount of the pharmaceutical composition of any one of claims 117, 118, or 164 effective to decrease the activity of the GALR2 receptor in the subject, thereby treating the abnormality in the subject.

### Claim 167 (depends on 166)

The method of claim 166, wherein the abnormality is obesity or bulimia.

### Claim 168 (depends on 115, 116)

A method of treating an abnormality in a subject wherein the abnormality is alleviated by the activation of a GALR2 receptor which comprises administering to a subject an effective amount of the pharmaceutical composition of any one of claims 115, 116, or 163 effective to activate the GALR2 receptor in the subject.

### Claim 169 (depends on 168)

The method of claim 168, wherein the abnormal condition is anorexia.

### Claim 170 (depends on 166, 168)

The method of claim 166 or 168, wherein the compound binds selectively to a GALR2 receptor.

### Claim 171 (depends on 170)

The method of claim 170, wherein the compound binds to the GALR2 receptor with an affinity greater than ten-fold higher than the affinity with which the compound binds to a GALR1 receptor.

### Claim 172 (depends on 170)

The method of claim 170, wherein the compound binds to the GALR2 receptor with an affinity greater than ten-fold higher than the affinity with which the compound binds to a GALR3 receptor.

### Claim 173 (depends on 65)

A method of detecting the presence of a GALR2 receptor on the surface of a cell which comprises contacting the cell with the antibody of claim 65 under conditions permitting binding of the antibody to the receptor, detecting the presence of the antibody bound to the cell, and thereby detecting the presence of a GALR2 receptor on the surface of the cell.

### Claim 174 (depends on 80)

A method of determining the physiological effects of varying levels of activity of GALR2 receptors which comprises producing a transgenic nonhuman mammal of claim 80 whose levels of GALR2 receptor activity are varied by use of an inducible promoter which regulates GALR2 receptor expression.

### Claim 175 (depends on 79)

A method of determining the physiological effects of varying levels of activity of GALR2 receptors which comprises producing a panel of transgenic nonhuman mammals of claim 79 each expressing a different amount of GALR2 receptor.

### Claim 176 (depends on 76, 79, 80)

A method for identifying an antagonist capable of alleviating an abnormality wherein the abnormality is alleviated by decreasing the activity of a GALR2 receptor comprising administering a compound to the transgenic nonhuman mammal of any one of claims 76, 79, 80, or 81, and determining whether the compound alleviates the physical and behavioral abnormalities displayed by the transgenic nonhuman mammal as a result of overactivity of a GALR2 receptor, the alleviation of the abnormality identifying the compound as an antagonist.

### Claim 177 (depends on 176)

An antagonist identified by the method of claim 176.

### Claim 178 (depends on 174)

A pharmaceutical composition comprising an antagonist identified by the method of claim 174 and a pharmaceutically acceptable carrier.

### Claim 179 (depends on 178)

A method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a GALR2 receptor which comprises administering to a subject an effective amount of the pharmaceutical composition of claim 178, thereby treating the abnormality.

### Claim 180 (depends on 76, 79, 80)

A method for identifying an agonist capable of alleviating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a GALR2 receptor comprising administering a compound to the transgenic nonhuman mammal of any one of claims 76, 79, 80, or 81, and determining whether the compound alleviates the physical and behavioral abnormalities displayed by the transgenic nonhuman mammal, the alleviation of the abnormality identifying the compound as an agonist.

### Claim 181 (depends on 180)

An agonist identified by the method of claim 180.

### Claim 182 (depends on 180)

A pharmaceutical composition comprising an agonist identified by the method of claim 180 and a pharmaceutically acceptable carrier.

### Claim 183 (depends on 182)

A method for treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a GALR2 receptor which comprises administering to a subject an effective amount of the pharmaceutical composition of claim 182, thereby treating the abnormality.

### Claim 184 (depends on 9)

A method for diagnosing a predisposition to a disorder associated with the activity of a specific human GALR2 receptor allele which comprises:
a. obtaining DNA of subjects suffering from the disorder;
b. performing a restriction digest of the DNA with a panel of restriction enzymes;
c. electrophoretically separating the resulting DNA fragments on a sizing gel;
d. contacting the resulting gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a human GALR2 receptor and labelled with a detectable marker;
e. detecting labelled bands which have hybridized to the DNA encoding a human GALR2 receptor of claim 9 labelled with a detectable marker to create a unique band pattern specific to the DNA of subjects suffering from the disorder;
f. preparing DNA obtained for diagnosis by steps a-e; and
g. comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step e and the DNA obtained for diagnosis from step f to determine whether the patterns are the same or different and to diagnose thereby predisposition to the disorder if the patterns are the same.

### Claim 185 (depends on 184)

The method of claim 184, wherein a disorder associated with the activity of a specific human GALR2 receptor allele is diagnosed.

### Claim 186 (depends on 26)

A method of preparing the purified GALR2 receptor of claim 26, which comprises:
a. inducing cells to express GALR2 receptor;
b. recovering the receptor from the induced cells; and
c. purifying the receptor so recovered.

### Claim 187 (depends on 26)

A method of preparing the purified GALR2 receptor of claim 26, which comprises:
a. inserting nucleic acid encoding the GALR2 receptor in a suitable vector;
b. introducing the resulting vector in a suitable host cell;
c. placing the resulting cell in suitable condition permitting the production of the isolated GALR2 receptor;
d. recovering the receptor produced by the resulting cell; and
e. purifying the receptor so recovered.

### Claim 188

A method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound which is a GALR2 receptor agonist or antagonist effective to increase or decrease the consumption of food by the subject so as to thereby modify feeding behavior of the subject.

### Claim 189 (depends on 188)

The method of claim 188, wherein the compound is a GALR2 receptor antagonist and the amount is effective to decrease the consumption of food by the subject.

### Claim 190 (depends on 188, 189)

The method of claim 188 or 189, wherein the compound is administered in combination with food.

### Claim 191 (depends on 188)

The method of claim 188, wherein the compound is a GALR2 receptor agonist and the amount is effective to increase the consumption of food by the subject.

### Claim 192 (depends on 188, 191)

The method of claim 188 or 191, wherein the compound is administered in combination with food.

### Claim 193 (depends on 188, 191)

The method of claim 188 or 191, wherein the compound binds selectively to a GALR2 receptor.

### Claim 194 (depends on 193)

The method of claim 193, wherein the compound binds to the GALR2 receptor with an affinity greater than ten-fold higher than the affinity with which the compound binds to a GALR1 receptor.

### Claim 195 (depends on 193)

The method of claim 193, wherein the compound binds to the GALR2 receptor with an affinity greater than ten-fold higher than the affinity with which the compound binds to a GALR3 receptor.

### Claim 196 (depends on 193)

The method of claim 193, wherein the compound binds to the GALR2 receptor with an affinity greater than one hundred-fold higher than the affinity with which the compound binds to a GALR1 receptor.

### Claim 197 (depends on 193)

The method of claim 193, wherein the compound binds to the GALR2 receptor with an affinity greater than one hundred-fold higher than the affinity with which the compound binds to a GALR3 receptor.

### Claim 198 (depends on 188)

The method of claim 188, wherein the subject is a vertebrate, a mammal, a human or a canine.

### Claim 199

A method for determining whether a compound is a GALR2 antagonist which comprises:
(a) administering to an animal a GALR2 agonist and measuring the amount of food intake in the animal;
(b) administering to a second animal both the GALR2 agonist and the compound, and measuring the amount of food intake in the second animal; and
(c) determining whether the amount of food intake is reduced in the presence of the compound relative to the amount of food intake in the absence of the compound, so as to thereby determine whether the compound is a GALR2 antagonist.

### Claim 200 (depends on 134)

A method of screening a plurality of compounds to identify a compound which is a GALR2 antagonist which comprises:
(a) administering to an animal a GALR2 agonist and measuring the amount of food intake in the animal;
(b) administering to a second animal the GALR2 agonist and at least one compound of the plurality of compounds and measuring the amount of food intake in the animal;
(c) determining whether the amount of food intake is reduced in the presence of at least one compound of the plurality relative to the amount of food intake in the absence of at least one compound of the plurality, and if so;
(d) separately determining whether each compound is a GALR2 antagonist according to the method of claim 134, so as to thereby identify a compound which is a GALR2 antagonist.

### Claim 201 (depends on 199, 200)

The method of claim 199 or 200, wherein the GALR2 agonist is [D-Trp]2-galanin(1-29).

### Claim 202 (depends on 199, 200)

The method of either of claims 199 or 200 wherein the animal is a non-human mammal.

### Claim 203 (depends on 202)

The method of claim 202, wherein the mammal is a rodent.

### Claim 204 (depends on 82, 83)

A process of claim 82 or 83, which further comprises determining whether the compound selectively binds to the GALR2 receptor relative to another galanin receptor.

### Claim 205 (depends on 204)

The process of claim 204, wherein the determination whether the compound selectively binds to the GALR2 receptor comprises:
(a) determining the binding affinity of the compound for the GALR2 receptor and for such other galanin receptor; and
(b) comparing the binding affinities so determined, the presence of a higher binding affinity for the GALR2 receptor than for such other galanin receptor indicating that the compound selectively binds to the GALR2 receptor.

### Claim 206 (depends on 204)

A process of claim 204, wherein such other galanin receptor is a GALR1 receptor.

### Claim 207 (depends on 204)

A process of claim 204, wherein such other galanin receptor is a GALR3 receptor.

### Claim 208 (depends on 91, 92, 93)

A process of any one of claims 91, 92 or 93, which further comprises determining whether the compound selectively activates the GALR2 receptor relative to another galanin receptor.

### Claim 209 (depends on 208)

The process of claim 208, wherein the determination whether the compound selectively activates the GALR2 receptor comprises:
(a) determining the potency of the compound for the GALR2 receptor and for such other galanin receptor; and
(b) comparing the potencies so determined, the presence of a higher potency for the GALR2 receptor than for such other galanin receptor indicating that the compound selectively activates the GALR2 receptor.

### Claim 210 (depends on 209)

A process of claim 209, wherein such other galanin receptor is a GALR1 receptor.

### Claim 211 (depends on 209)

A process of claim 209, wherein such other galanin receptor is a GALR3 receptor.

### Claim 212 (depends on 99, 100)

A process of claim 99 or 100, which further comprises determining whether the compound selectively inhibits the activation of the GALR2 receptor relative to another galanin receptor.

### Claim 213 (depends on 212)

The process of claim 212, wherein the determination whether the compound selectively inhibits the activation of the GALR2 receptor comprises:
(a) determining the decrease in the potency of a known galanin receptor agonist for the GALR2 receptor in the presence of the compound, relative to the potency of the agonist in the absence of the compound;
(b) determining the decrease in the potency of the agonist for such other galanin receptor in the presence of the compound, relative to the potency of the agonist in the absence of the compound; and
(c) comparing the decrease in potencies so determined, the presence of a greater decrease in potency for the GALR2 receptor than for such other galanin receptor indicating that the compound selectively inhibits the activation of the GALR2 receptor.

### Claim 214 (depends on 213)

A process of claim 213, wherein such other galanin receptor is a GALR1 receptor.

### Claim 215 (depends on 213)

A process of claim 213, wherein such other galanin receptor is a GALR3 receptor.

### Claim 216

A method of decreasing feeding behavior of a subject which comprises administering a compound which is a GALR2 receptor antagonist and a compound which is a Y5 receptor antagonist, the amount of such antagonists being effective to decrease the feeding behavior of the subject.

### Claim 217 (depends on 216)

The method of claim 216, wherein the GALR2 antagonist and the Y5 antagonist are administered in combination.

### Claim 218 (depends on 216)

The method of claim 216, wherein the GALR2 antagonist and the Y5 antagonist are administered once.

### Claim 219 (depends on 216)

The method of claim 216, wherein the GALR2 antagonist and the Y5 antagonist are administered separately.

### Claim 220 (depends on 219)

The method of claim 219, wherein the GALR2 antagonist and the Y5 antagonist are administered once.

### Claim 221 (depends on 219)

The method of claim 219, wherein the galanin receptor antagonist is administered for about 1 week to 2 weeks.

### Claim 222 (depends on 219)

The method of claim 219, wherein the Y5 receptor antagonist is administered for about 1 week to 2 weeks.

### Claim 223 (depends on 219)

The method of claim 219, wherein the GALR2 antagonist and the Y5 antagonist are administered alternately.

### Claim 224 (depends on 223)

The method of claim 223, wherein the GALR2 antagonist and the Y5 antagonist-are administered repeatedly.

### Claim 225 (depends on 223, 224)

A method of claim 223 or 224, wherein the galanin receptor antagonist is administered for about 1 week to 2 weeks.

### Claim 226 (depends on 223, 224)

A method of claim 223 or 224, wherein the Y5 receptor antagonist is administered for about 1 week to 2 weeks.

### Claim 227 (depends on 216, 217, 218)

A method of any one of claims 216, 217, 218, or 219, wherein the compound is administered in a pharmaceutical composition comprising a sustained release formulation.

### Claim 228

A method of decreasing nociception in a subject which comprises administering to the subject an amount of a compound which is a GALR2 receptor agonist effective to decrease nociception in the subject.

### Claim 229

A method of treating pain in a subject which comprises administering to the subject an amount of a compound which is a GALR2 receptor agonist effective to treat pain in the subject.

### Claim 230

A method of treating Alzheimer's disease in a subject which comprises administering to the subject an amount of a compound which is a GALR2 receptor antagonist effective to treat Alzheimer's disease in the subject.
